J&J: Working together, not marketing together

Johnson & Johnson says it's not planning to coordinate marketing of consumer and prescription products as the Financial Times had reported, but to share information among its various businesses to better identify patients' needs. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.